A5072359465- CAR-T cell therapy research
- Transgenic Plants and Applications
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
- Viral Infectious Diseases and Gene Expression in Insects
- Toxin Mechanisms and Immunotoxins
- Immune cells in cancer
- Immune Cell Function and Interaction
- Phagocytosis and Immune Regulation
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- Oral Health Pathology and Treatment
- Pancreatic function and diabetes
- Hedgehog Signaling Pathway Studies
- Cancer, Hypoxia, and Metabolism
- Lymphoma Diagnosis and Treatment
- Biomarkers in Disease Mechanisms
- Angiogenesis and VEGF in Cancer
- Insect Resistance and Genetics
- TGF-β signaling in diseases
- RNA Interference and Gene Delivery
- Flavonoids in Medical Research
- Phytochemicals and Medicinal Plants
- Pancreatic and Hepatic Oncology Research
Chittaranjan National Cancer Institute
2020-2024
Introduction Non-Hodgkin Lymphoma (NHL) is a heterogeneous lymphoproliferative malignancy with B cell origin. Combinatorial treatment of rituximab, cyclophsphamide, hydroxydaunorubicin, oncovin, prednisone (R-CHOP) the standard regimen for NHL, yielding complete remission (CR) rate 40-50%. Unfortunately, considerable patients undergo relapse after CR or initial treatment, resulting in poor clinical implications. Patient’s response to chemotherapy varies widely from static disease cancer...
Abstract Heterogeneity within the tumor-infiltrating lymphocytes (TIL) population limits immunotherapeutic efficacy against cancer. Between two subpopulations of exhausted CD8+ TILs (progenitor-exhausted; TPEX, terminally exhausted; TTEX), TTEX cells remain unresponsive to anti–programmed cell death protein 1(PD-1) therapy. Deciphering whether and how PD-1–resistant engage in tumor promotion could improve response immunotherapy. Here, we report that actively participate progression by...
Abstract Background A water-soluble ingredient of mature leaves the tropical mahogany ‘Neem’ ( Azadirachta indica ), was identified as glycoprotein, thus being named ‘Neem Leaf Glycoprotein’ (NLGP). This non-toxic leaf-component regressed cancerous murine tumors (melanoma, carcinoma, sarcoma) recurrently in different experimental circumstances by boosting prime antitumor immune attributes. Such immunomodulation, aid cytotoxic T cell (T c )-based annihilation tumor cells. study focused on...
<p>Contains supplementary figure S1, S2, S3, S4, S5 and S6.</p>
Aim: As tumor causes atrophy in the thymus to target effector-T cells, this study is aimed decipher efficacy of neem leaf glycoprotein (NLGP) tumor- and age-associated thymic atrophy. Materials & methods: Different parameters were studied using flow cytometry, reverse transcriptase PCR immunocyto-/histochemistry murine melanoma sarcoma models. Results: Longitudinal NLGP therapy hosts show tumor-reduction along with significant normalization alterations. downregulates intrathymic IL-10, which...
Introduction Murine tumor growth restriction by neem leaf glycoprotein (NLGP) was established in various transplanted models of murine sarcoma, melanoma and carcinoma. However, the role NLGP sequential carcinogenic steps has not been explored. Thus, tongue carcinogenesis Swiss mice induced 4-nitroquinoline-1-oxide (4NQO), which close resemblance to human process. Interventional initiation-promotion protocol during 4NQO mediated relation systemic immune alteration epithelial-mesenchymal...
Abstract Epidemiological studies suggest that patients with pre-existing type 1 diabetes (T1D) have a decreased risk of developing melanoma, prostate cancer, and breast although the underlying mechanism remains to be elucidated. In translational modelling, we observed streptozotocin (STZ) induced T1D mice exhibited restricted melanoma carcinoma (mammary, lung colon) growth in association extended overall survival. Tumor-infiltrating CD8 + T cells were found responsible for tumor restriction....
Targeting exhausted CD8+ T-cell (TEX)-induced aggravated cancer stem cells (CSC) holds immense therapeutic potential. In this regard, immunomodulation via Neem Leaf Glycoprotein (NLGP), a plant-derived glycoprotein immunomodulator is explored. Since former reports have proven immune dependent-tumor restriction of NLGP across multiple tumor models, we hypothesized that might reprogram and rectify TEX to target CSCs successfully. study, report NLGP's administration significantly reduced...
<div>Abstract<p>Targeting exhausted CD8<sup>+</sup> T-cell (T<sub>EX</sub>)–induced aggravated cancer stem cells (CSC) holds immense therapeutic potential. In this regard, immunomodulation via Neem Leaf Glycoprotein (NLGP), a plant-derived glycoprotein immunomodulator is explored. Since former reports have proven immune dependent–tumor restriction of NLGP across multiple tumor models, we hypothesized that might reprogram and rectify...
<p>The file contains Supplementary Figure S2</p>
<p>The file contains Supplementary Figure S7</p>
<div>Abstract<p>Targeting exhausted CD8<sup>+</sup> T-cell (T<sub>EX</sub>)–induced aggravated cancer stem cells (CSC) holds immense therapeutic potential. In this regard, immunomodulation via Neem Leaf Glycoprotein (NLGP), a plant-derived glycoprotein immunomodulator is explored. Since former reports have proven immune dependent–tumor restriction of NLGP across multiple tumor models, we hypothesized that might reprogram and rectify...
<p>The file contains Supplementary Figure S4</p>
<p>The file contains Supplementary Figure S5</p>
<p>The file contains Supplementary Figure S3</p>
<p>The file contains Supplementary Figure S3</p>
<p>The file contains Supplementary Figure S5</p>
<p>The file contains Supplementary Figure S1</p>
<p>The file contains Supplementary Figure S4</p>
<p>The file contains Supplementary Figure S6</p>